Monday, February 24, 2014 10:11:36 AM
Advanced Cell Technology Shelves Myoblast Program...
"What most don't realize, is that they had a trial (Myoblast) that was approved for phase II trials back in 2008. The cost to start it up was estimated @ 15M, but instead of funding the heart trials, they wasted $$$ on expensive administration, and free stock handouts to themselves worth millions. Then they had the audacity to blame the government, religious groups, and eventually the investors for playing a role in their struggles.
They were also supposed to have had trials that were blood related (HG) since 2008, but that was all a farce as well and the company simply used this to hype up investors into thinking that big things were right around the corner. In reality, the only thing big in their plans was diluting shareholders with toxic financing and poor management decisions."
ACTC
"What most don't realize, is that they had a trial (Myoblast) that was approved for phase II trials back in 2008. The cost to start it up was estimated @ 15M, but instead of funding the heart trials, they wasted $$$ on expensive administration, and free stock handouts to themselves worth millions. Then they had the audacity to blame the government, religious groups, and eventually the investors for playing a role in their struggles.
They were also supposed to have had trials that were blood related (HG) since 2008, but that was all a farce as well and the company simply used this to hype up investors into thinking that big things were right around the corner. In reality, the only thing big in their plans was diluting shareholders with toxic financing and poor management decisions."
ACTC
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
